BCLI Brainstorm Cell Therapeutics Inc.

3.78
0  0%
Previous Close 3.78
Open
Price To Book 189
Market Cap 111,474,506
Shares 29,490,610
Volume 0
Short Ratio
Av. Daily Volume 45,079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data mid-2020.
NurOwn
Amytrophic lateral sclerosis (ALS)
Phase 2 commencement of enrolment announced March 14, 2019.
NurOwn
Progressive Multiple Sclerosis

Latest News

  1. BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
  2. BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
  3. BrainStorm Senior Management to Present at BIO 2019
  4. BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19…
  5. BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
  6. BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
  7. BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
  8. BCLI: Two Abstracts to be Presented at AAN Annual Meeting…
  9. Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
  10. BrainStorm Announces Grant of an additional New European Patent for NurOwn®
  11. Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement
  12. BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…
  13. BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
  14. Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
  15. The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
  16. BrainStorm to Host Business Update Conference Call
  17. BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
  18. BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
  19. BrainStorm Issues a Statement to Patients and Shareholders
  20. BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium